Notice of Intent to Sole Source – Intera 3000 Hepatic Artery Infusion Pumps (NIH/NCI)
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR), Surgical Oncology Program (SOP), intends to award a sole source Firm-Fixed-Price contract to Inter Oncology Inc. for the procurement of Intera 3000 Hepatic Artery Infusion Pumps. This action supports an IRB-approved clinical protocol. Capability statements from other responsible sources are due by March 24, 2026.
Scope of Work
This procurement is for Intera 3000 Hepatic Artery Infusion Pumps. These devices are required to support an IRB-approved clinical protocol involving hepatic artery infusion therapy for oncology patients. The award will include option line items for additional pumps, exercisable individually as needed based on clinical enrollment and treatment requirements. The base period of performance is anticipated from April 6, 2026, through April 5, 2027.
Contract & Timeline
- Contract Type: Firm-Fixed-Price
- Intended Awardee: Inter Oncology Inc.
- Base Period of Performance: April 6, 2026, through April 5, 2027. Option periods may vary.
- Response Deadline: March 24, 2026, by 10:00 A.M. Eastern Time.
- Published Date: March 9, 2026
Sole Source Rationale
This acquisition is being conducted under FAR Subpart 13.5 and 41 U.S.C. 3304(a)(1), as market research determined that the Intera 3000 Hepatic Artery Infusion Pump is the only FDA-approved device available for this specific clinical indication. Substitution with an alternate device is not feasible, as it would introduce clinical risk, disrupt the IRB-approved protocol, and potentially compromise patient safety. Therefore, Inter Oncology Inc. is considered the only responsible source capable of meeting the Government's requirement.
Response Information
This notice is not a request for competitive quotations. However, any responsible source that believes it can provide the required FDA-approved Hepatic Artery Infusion Pumps may submit a capability statement demonstrating its ability to meet the Government's requirement. Responses must be submitted via email to Nien-tzu.Wang@hhs.gov by the stated deadline. Information received will be considered solely to determine if a competitive procurement is feasible.
NAICS Code
- NAICS Code: 339112 – Surgical and Medical Instrument Manufacturing
- Size Standard: 1,000 employees